

ESMO PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
3-4 April 2024

CO-CHAIRS

Laurence Albiges, France
Viktor Grünwald, Germany

SPEAKERS

Axel Bex, The Netherlands
Guillermo De Velasco, Spain
Karin Kastrati, Germany
Niklas Klümper, Germany
Géraldine Pignot, France
Bernadett Szabados, United Kingdom
Michiel van der Heijden, The Netherlands
Ursula Vogl, Switzerland

LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

Wednesday, 3 April 2024

09:00-09:15 15'	Opening and welcome	Laurence Albiges, FR Viktor Grünwald, DE
15'	Welcome from ESMO - Objectives and scientific introduction	Laurence Albiges, FR Viktor Grünwald, DE
09:15-10:15 60'	SESSION 1 Bladder Cancer – Part I	Chairs: Michiel van der Heijden, NL Ursula Vogl, CH
15'	Localized and systemic standard treatments in muscle-invasive bladder cancer	Géraldine Pignot, FR
15'	Approaches to upper tract UC	Géraldine Pignot, FR
15'	FGR inhibitor and ADC toxicity management	Michiel van der Heijden, NL
15'	Q&A	All
10:15-10:45	Coffee break	

10:45-12:30 105'	SESSION 2 Bladder Cancer – Part II	Chairs: Viktor Grünwald, DE Géraldine Pignot, FR
15'	Neoadjuvant treatments for MIBC	Ursula Vogl, CH
15'	First line treatment in advanced bladder cancer	Michiel van der Heijden, NL
15'	Second line and beyond in advanced bladder cancer	Bernadett Szabados, UK
15'	Biomarkers beyond PD-L1 in metastatic bladder cancer	Niklas Klümper, DE
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty

12:30-13:30	Lunch
--------------------	--------------

13:30-15:00 90'	SESSION 3 Renal Cancer – Part I	Chairs: Laurence Albiges, FR Viktor Grünwald, DE
25'	How to treat primary tumour: <ul style="list-style-type: none"> - Surgery and other techniques - A role for neoadjuvant treatment - A role for nephrectomy in advanced disease 	Axel Bex, NL
10'	Oligometastatic disease management	Guillermo De Velasco, ES
15'	Q&A	All
40'	Participants clinical case discussion (4x10')	Faculty

15:00-15:30	Coffee Break
--------------------	---------------------

15:30-17:30 120'	SESSION 4 Debate around adjuvant therapy for Bladder and RCC	Chairs: Géraldine Pignot, FR Guillermo De Velasco, ES
15'	Summary of adjuvant therapies for Bladder and RCC	Bernadett Szabados, UK
10'	Biomarker guided strategy	Niklas Klümper, DE
10'	Surgeon point of view: Assessing the risk of relapse	Axel Bex, NL
15'	Patient's advocate point of view	Karin Kastrati, DE
15'	Treatment after progression on adjuvant therapy in renal and bladder cancer	Ursula Vogl, CH
25'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty

20:00	Dinner
--------------	---------------

Thursday, 4 April 2024

09:00-10:25 85'	SESSION 5 Renal Cancer – Part II	Chairs: Guillermo De Velasco, ES Ursula Vogl, CH
20'	Debate: Immune combinations or VEGF/PD1 inhibition as 1st line therapy for advanced clear cell RCC - Immune combinations - VEGF/PD1 inhibition	Laurence Albiges, FR Viktor Grünwald, DE
30'	Individualized therapy in frontline and beyond	Laurence Albiges, FR
20'	Biology and treatment of non-clear RCC	Bernadett Szabados, UK
15'	Q&A	All
10:25-10:55	Coffee break	
10:55-12:40 105'	SESSION 6 Focus on toxicity and duration of therapy	Chair: Laurence Albiges, FR
15'	Can we stop targeted therapy, immune therapy?	Viktor Grünwald, DE
15'	How to handle oligoprogressive disease	Guillermo De Velasco, ES
15'	New treatments and approaches to NMIBC	Niklas Klümper, DE
15'	How to monitor and account for PRO endpoint	Karin Kastrati, DE
15'	Q&A	All
30'	Participants clinical case discussion (3x10')	Faculty
12:40-12:50 10'	Conclusion and farewell	Laurence Albiges, FR Viktor Grünwald, DE
12:50-13:50	Lunch	

Note: Each 10 minute slot for participant clinical case discussion includes a 5' case presentation and a 5' Q&A / discussion